And is there a statistically significant change in the mortality rate? That is the area remestemcel-L is aimed at. While getting people who will recover better sooner is good for them and freeing up hospital beds it does not stop people dying.
Perhaps the outcome of that trial is why Remdesivir is still described like this in the
Fact Sheet for Patients And Parents/Caregivers
Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)
https://www.fda.gov/media/137565/download
If there were the resources available it would be interesting to see MATH+ and Remdesivir head on in a PCT.
MSB Trading - 2020, page-19054
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |